Summary
Quest Diagnostics Incorporated (DGX) filed an 8-K on December 17, 2004, reporting key changes to its governance and compensation practices. The company's Board of Directors approved an amendment to its Stock Option Plan for Non-Employee Directors, shifting from the Black-Scholes methodology to lattice methodology for calculating share values underlying option grants, effective January 1, 2005. This change in valuation method for director compensation could potentially impact the number of shares issued under these options. Furthermore, the filing details a significant change in the Board composition. Kenneth W. Freeman resigned as a director, while Gary M. Pfeiffer was elected to the Board and appointed to the Audit and Finance Committee. Mr. Pfeiffer, currently the CFO of E.I. DuPont de Nemours and Company, has been deemed an independent director and an "audit committee financial expert" by the Board, aligning with NYSE and SEC requirements. These updates reflect adjustments in executive compensation strategy and strengthening of the Board's oversight capabilities.
Key Highlights
- 1Amendment to the Director Stock Option Plan approved, changing valuation methodology from Black-Scholes to lattice from January 1, 2005.
- 2This change in methodology for director stock options could affect the number of shares underlying grants.
- 3Kenneth W. Freeman resigned from the Board of Directors on December 14, 2004.
- 4Gary M. Pfeiffer elected as a new independent director to the Board.
- 5Gary M. Pfeiffer appointed to the Audit and Finance Committee.
- 6Mr. Pfeiffer, CFO of DuPont, is recognized as an 'audit committee financial expert' under SEC rules.
- 7The company is updating its director compensation valuation method and adding financial expertise to its board.